Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
21. |
ECCT/24/12/03 | PrEMIA Implementation study Multi-product PrEP delivery to young women seeking reproductive health services and coverage of HIV prevention |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya KEMRI-CCR PHRD( (THIKA) PROJECT |
View |
22. |
ECCT/24/12/02 | IAVI C113 IAVI C113: A Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in interferon gamma release assay positive adolescents and adults aged 14-45 years, living in a TB endemic region. |
Principal Investigator(s) 1. Videlis Nduba 2. Tina Lucas Site(s) in Kenya 1. KEMRI,Centre for Respiratory Diseases Research (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) |
View |
23. |
ECCT/24/12/01 | PDMC-Saves Lives (PDMC-SL) Delivery strategies for malaria chemoprevention in the post-discharge management of hospitalised children with severe anaemia or severe malaria: cluster and individually randomised controlled implementation trials with nested economic evaluation in Kenya and Benin |
Principal Investigator(s) 1. Juliet Otieno Awori 2. Simon Kariuki Site(s) in Kenya Health facilities with blood transfusion services in malaria-endemic areas in Western Kenya |
View |
24. |
ECCT/24/11/03 | REALISE STUDY PROTOCOL A Pragmatic Phase III Multi-Centre Clinical Trial to Evaluate the Safety and 1 Effectiveness of a Single Dose of an Albendazole-Ivermectin Coformulation vs 2 Albendazole for Preventive Chemotherapy of Soil-Transmitted Helminth Infections in 3 School-Aged Children |
Principal Investigator(s) 1. Alejandro Javier Krolewiecki Site(s) in Kenya Kwale county |
View |
25. |
ECCT/24/11/01 | Sparkle A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. Site 1401:Victoria Biomedical Research Institute (Kisumu county) 2. Site 1402:Ahero Clinical trials Unit (Kisumu county) 3. Site 1403:International Cancer institute (Uasin Gishu county) 4. Site 1404:Kondele Childrens Hospital (Kisumu county) 5. Site 1405:KEMRI/CRDR KEMRI Clinical Research Annex (Kisumu county) 6. Site 1406:Gertrudes Children’s Hospital (Nairobi City county) |
View |